Death or Damage of Dopamine Neurons

The hallmark pathology of Parkinson’s disease is the damage and death of dopamine producing neurons in the brain. 

By | February 1, 2011

Infographic: Death or Damage of Dopamine Neurons
View full size JPG | PDF
LUCY READING-IKKANDA

The hallmark pathology of Parkinson’s disease is the damage and death of dopamine producing neurons in the brain. Dopamine plays a role in controlling movement, cognition, learning, and mood, explaining the dementia and difficulty with motor control exhibited by patients with deficits in the production of this key neurotransmitter. The a-synuclein gene was one of the first to be implicated in this disease. It produces a protein that can, in certain circumstances, aggregate to form bundles that are a major component of Lewy bodies—fibers that disrupt normal cell processes. Recently researchers have discovered other mechanisms by which this protein damages or kills dopamine-producing neurons, as well as other genes that may also play a role in driving the disease.

Read the full story.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  2. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. EPO Revokes Broad’s CRISPR Patent
    The Nutshell EPO Revokes Broad’s CRISPR Patent

    Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely—and more are likely to follow.

AAAS